Payment overview · 2025
General Payments
$227.49
11 reported records · 3 companies
Healthcare provider profile · identity verified
John Wesley Greene, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIDDLETOWN, OH · NPI 1275956617
Verified facts
What the public records show
CMS Open Payments records show John Wesley Greene, CNP received $227.49 in general payments during 2025 across 11 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 85.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $193.66 | 85.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.86 | 8.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.97 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $227.49 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $193.66 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 834 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 519 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 505 | 126 |
| Gabapentin | Gabapentin | 485 | 109 |
| Losartan Potassium | Losartan Potassium | 441 | 105 |
| Omeprazole | Omeprazole | 377 | 87 |
| Lisinopril | Lisinopril | 339 | 78 |
| Metformin Hcl | Metformin Hcl | 324 | 69 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 308 | 71 |
| Diclofenac Sodium | Diclofenac Sodium | 289 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 63 |
| Ibuprofen | Ibuprofen | 235 | 61 |
| Montelukast Sodium | Montelukast Sodium | 220 | 37 |
| Glimepiride | Glimepiride | 196 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 192 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 192 | 33 |
| Trulicity | Dulaglutide | 190 | 35 |
| Trazodone Hcl | Trazodone Hcl | 182 | 49 |
| Famotidine | Famotidine | 181 | 42 |
| Furosemide | Furosemide | 171 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 37 |
| Baclofen | Baclofen | 162 | 39 |
| Sertraline Hcl | Sertraline Hcl | 155 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 45 |
| Single Use Swab | Alcohol Antiseptic Pads | 141 | 45 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 136 | 40 |
| Ventolin Hfa | Albuterol Sulfate | 132 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 46 |
| Potassium Chloride | Potassium Chloride | 125 | 29 |
| Metformin Hcl Er | Metformin Hcl | 124 | 25 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 118 | 20 |
| Januvia | Sitagliptin Phosphate | 113 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 33 |
| Mirtazapine | Mirtazapine | 104 | 19 |
| Meclizine Hcl | Meclizine Hcl | 98 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 97 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 97 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 24 |
| Chlorthalidone | Chlorthalidone | 92 | 18 |
| Spironolactone | Spironolactone | 91 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 90 | 22 |
| Meloxicam | Meloxicam | 86 | 25 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 84 | 22 |
| Glipizide | Glipizide | 81 | suppressed |
| Levetiracetam | Levetiracetam | 81 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 18 |
| Carvedilol | Carvedilol | 76 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 76 | 18 |
| Novolog Flexpen | Insulin Aspart | 75 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 18 |
| Propranolol Hcl | Propranolol Hcl | 71 | 12 |
| Alendronate Sodium | Alendronate Sodium | 70 | 20 |
| Atenolol | Atenolol | 70 | 16 |
| Nifedipine Er | Nifedipine | 67 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 61 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 17 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Ondansetron Odt | Ondansetron | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 52 | 13 |
| Methocarbamol | Methocarbamol | 52 | 23 |
| Arnuity Ellipta | Fluticasone Furoate | 51 | 13 |
| Promethazine Hcl | Promethazine Hcl | 50 | 11 |
| Tradjenta | Linagliptin | 50 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 49 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 48 | 13 |
| Jardiance | Empagliflozin | 48 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 48 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 46 | 12 |
| Ozempic | Semaglutide | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 11 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 11 |
| Allopurinol | Allopurinol | 38 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Indomethacin | Indomethacin | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | 11 |
| Admelog Solostar | Insulin Lispro | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 21 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Prednisone | Prednisone | 22 | 18 |
| Lidocaine | Lidocaine | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sure Comfort | Pen Needle, Diabetic | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $227.49 · 11 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error